Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > T14 TJ DaRenTang USD > Detailed Quotes

T14 TJ DaRenTang USD

Watchlist
1.1900.0000.00%
10 Minutes Delay  Market Close  02/07 17:06 CCT
High
1.220
Open
1.210
Turnover
417.80K
Low
1.190
Pre Close
1.190
Volume
347.00K
Market Cap
920.40M
P/E(TTM)
7.83
52wk High
1.230
Shares
773.44M
P/E(Static)
7.58
52wk Low
0.847
Float Cap
498.66M
Bid/Ask %
11.82%
Historical High
1.525
Shs Float
419.04M
Volume Ratio
0.72
Historical Low
-0.452
Dividend TTM
0.07
Div Yield TTM
0.047
P/B
0.93
Dividend LFY
5.88%
Div Yield LFY
3.95%
Turnover Ratio
0.08%
Amplitude
2.52%
Avg Price
1.204
Lot Size
100
Float Cap
498.66M
Bid/Ask %
11.82%
Historical High
1.525
Shs Float
419.04M
Volume Ratio
0.72
Historical Low
-0.452
Dividend TTM
0.07
EPS TTM
0.152
P/B
0.93
Dividend LFY
5.88%
EPS LYR
0.157
Turnover Ratio
0.08%
Amplitude
2.52%
Lot Size
100
Price Forecast

News

Comment

Sign in to post a comment

    Q3 Result

    $TJ DaRenTang USD(T14.SG)$
    (a) Revenue: 
    The Group’s revenue in the third quarter of FY2021 (“3Q FY2021”) was approximately RMB 1,712 million, an increase of approximately RMB 45 million, or 3%, from RMB 1,667 million in the third quarter of FY2020 (“3Q FY2020”). For the 9 months ended 30 September 2021 (“9M 2021”), the Group recorded a revenue of approximately RMB 5,352 million, an increase of approximately RMB 395 million, approximately 8% over the corresponding period in FY2020. The increase in revenue as compared to the corresponding period last year was primarily because the revenue in the corresponding period last year was affected by the COVID-19 pandemic.  
    (b) Gross Profit Margin: 
    The Group’s gross profit in 3Q FY2021 increased by approximately 19% from approximately RMB 585 million in 3Q FY2020 to approximately RMB 696 million. For 9M 2021, the Group’s gross profit was approximately RMB 2,202 million compared to approximately RMB 1,935 million in the corresponding period of FY2020, with an increase of approximately 14% amounting to approximately RMB 268 million. The gross profit margin has increased from 39% in the 9 months ended 30 September 2020 (“9M 2020”) to 41% in 9M 2021.
    Comment
    Share

No comment yet

Company Overview More
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
CEO: --
Market: --
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Watchlist